Loading...
A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
Immune checkpoint inhibitors, such as monoclonal antibodies targeting programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1), have achieved enormous success in the treatment of several cancers. However, monoclonal antibodies are expensive to produce, have poor tumor penetration, and may ind...
Na minha lista:
| Udgivet i: | Front Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8160380/ https://ncbi.nlm.nih.gov/pubmed/34054817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.654463 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|